We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Test Helps Select Best Treatment for Bowel Cancer Patients

By LabMedica International staff writers
Posted on 01 Mar 2016
Print article
Image: Histopathology of advanced bowel adenocarcinoma in which the glands are much larger and filled with necrotic debris (Photo courtesy of University of Utah School of Medicine).
Image: Histopathology of advanced bowel adenocarcinoma in which the glands are much larger and filled with necrotic debris (Photo courtesy of University of Utah School of Medicine).
Doctors usually treat advanced bowel cancer, also known as colorectal cancer, with chemotherapy but sometimes the first course of chemotherapy does not work and they need to give a different type of chemotherapy known as second line of treatment.

In a recent clinical trial each patient had their cancer tested for a gene called rat sarcoma (RAS). If there were no faults in the gene, they went on to receive irinotecan either alone or together with a new targeted cancer drug called panitumumab. The study showed that some patients benefitted from adding the new drug but others did not and further studies were carried out to find out the reason.

Scientists at the St James’s University Hospital (Leeds, UK) and their colleagues studied tumor samples from 323 patients who were tested for levels of two proteins, called Amphiregulin (AREG) and Epiregulin (EREG), which are produced by some cancer cells to help them grow. Panitumumab blocks these proteins, stopping tumors developing. The analysis was conducted between 2012 and 2014. A predefined dichotomous model classified tumors as “high expressor” (either EREG or AREG in top tertile for messenger ribonucleic acid (mRNA) level) or “low expressor” (neither EREG nor AREG in top tertile). Ligand expression was assessed as a prognostic and predictive biomarker. Expression of AREG/EREG and RAS and BRAF mutations were assessed in archival tumor tissue.

The team showed that for patients with high levels of the proteins, the drug combination stopped cancer growth for nearly twice as long as irinotecan alone with a mean of eight months compared with four and a half months, but the drug did not work for patients with low levels of the proteins. High ligand expression is a predictive marker for panitumumab therapy benefit on progression-free survival (PFS) in RAS wild type (wt) patients; conversely, patients with low ligand expression gained no benefit. The current “opt-in” strategy for anti-EGFR therapy in all patients with RAS wt advanced colorectal cancer should be questioned. Expression of EREG/AREG is a useful biomarker for anti-EGFR therapy; optimization for clinical use is indicated.

Jenny F. Seligmann, PhD, the lead author, said, “These results are very promising. Our task now is to develop a fast and reliable test for the two proteins that can be offered to patients before they start treatment, to help select the right drugs to use. We now have new cancer drugs that work in very specific ways, targeting individual rogue molecules in cancer cells. These drugs can be of enormous help to some patients, but not others.” The study was published on February 11, 2016, in JAMA Oncology.

Related Links:

St James’s University Hospital 


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Automated Blood Typing System
IH-500 NEXT
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab
New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: This medium is used to grow malaria parasites (Photo courtesy of Kyle Dykes/UC San Diego Health Sciences)

New Approach to Help Predict Drug Resistance in Malaria and Infectious Diseases

Malaria, a disease transmitted by mosquitoes that affects millions worldwide, remains a significant public health concern, especially in tropical and subtropical regions. Despite significant efforts to... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.